Skip to content

Pharmacology of ayahuasca administered in two repeated doses

Rafael G. Dos Santos, Eva Grasa, Marta Valle, María Rosa Ballester, José Carlos Bouso, Josep Nomdedéu, R. Homs, Manel J. Barbanoj, Jordi Riba

Psychopharmacology August 12, 2011 DOI: 10.1007/s00213-011-2434-x via OpenAlex

Summary

AI-generated from the abstract

The human pharmacology of ayahuasca, an Amazonian tea containing the psychedelic DMT, was evaluated after repeated doses. In a double-blind, crossover, placebo-controlled trial, nine experienced psychedelic drug users received either a placebo followed by ayahuasca, or two ayahuasca doses four hours apart. DMT plasma concentrations, subjective and neurophysiological effects, and serum prolactin and cortisol were higher after two doses. When effects were adjusted for plasma DMT, no differences appeared for subjective, neurophysiological, autonomic, or immunological measures. A trend toward reduced systolic blood pressure and heart rate, and significant tolerance to growth hormone secretion, were observed after the second dose. No clear tolerance or sensitization occurred in psychological or most physiological variables.

Study at a glance

Characteristics Double-blind, crossover, placebo-controlled clinical trial Peer reviewed
Sample size 9
Population Experienced psychedelic drug users
Interventions Ayahuasca Lactose placebo
Dose 0.75 mg DMT/kg bodyweight
Duration 4-hour interval between doses, 12-hour total measurement period
Topics Ayahuasca
Keywords Placebo Crossover study Medicine Pharmacology
Citations 139
Key finding No clear tolerance or sensitization in psychological or most physiological variables, but a trend to lower cardiovascular activation and significant tolerance to growth hormone secretion after repeated ayahuasca doses.

Abstract

RationaleAyahuasca is an Amazonian tea containing the natural psychedelic 5-HT(2A/2C/1A) agonist N,N-dimethyltryptamine (DMT). It is used in ceremonial contexts for its visionary properties. The human pharmacology of ayahuasca has been well characterized following its administration in single doses.ObjectivesTo evaluate the human pharmacology of ayahuasca in repeated doses and assess the potential occurrence of acute tolerance or sensitization.MethodsIn a double-blind, crossover, placebo-controlled clinical trial, nine experienced psychedelic drug users received PO the two following treatment combinations at least 1 week apart: (a) a lactose placebo and then, 4 h later, an ayahuasca dose; and (b) two ayahuasca doses 4 h apart. All ayahuasca doses were freeze-dried Amazonian-sourced tea encapsulated to a standardized 0.75 mg DMT/kg bodyweight. Subjective, neurophysiological, cardiovascular, autonomic, neuroendocrine, and cell immunity measures were obtained before and at regular time intervals until 12 h after first dose administration.ResultsDMT plasma concentrations, scores in subjective and neurophysiological variables, and serum prolactin and cortisol were significantly higher after two consecutive doses. When effects were standardized by plasma DMT concentrations, no differences were observed for subjective, neurophysiological, autonomic, or immunological effects. However, we observed a trend to reduced systolic blood pressure and heart rate, and a significant decrease for growth hormone (GH) after the second ayahuasca dose.ConclusionsWhereas there was no clear-cut tolerance or sensitization in the psychological sphere or most physiological variables, a trend to lower cardiovascular activation was observed, together with significant tolerance to GH secretion.

Explore topics

Comments

No comments yet.

Log in to comment